The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma.
In a retrospective study, we calculated the treatment costs of 26 patients, who received either high dose melphalan combined with granulocyte colony-stimulating factor (G-CSF; filgrastim)(n = 7) or without G-CSF (n = 11) or alternatively, peripheral blood progenitor cell reinfusion (PBPC) mobilised by G-CSF following high dose melphalan. In comparison with the control group, a shortening of the pancytopenic period and platelet recovery was noticed in the PBPC group. This resulted in a reduction in hospital costs, diagnostics, laboratory services, total parenteral nutrition and transfusions. The average costs per treatment in the PBPC group amounted to about US$ 17,908 as compared to US$ 32,223 in the control group, implying a cost reduction of 44% when changing to PBPC reinfusion.
Uyl-de Groot
C A
CA
Institute for Medical Technology Assessment/Department of Health Care Policy and Management, Erasmus University, Rotterdam, The Netherlands.
Ossenkoppele
G J
GJ
van Riet
A A
AA
Rutten
F F
FF
D001804:Blood Transfusion, Autologous; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes; D017048:Health Care Costs; D018380:Hematopoietic Stem Cell Transplantation; D017721:Hospital Costs; D006801:Humans; D007902:Length of Stay; D007958:Leukocyte Count; D008558:Melphalan / Q000008:administration & dosage*; D009101:Multiple Myeloma / Q000191:economics / Q000628:therapy*; D010976:Platelet Count; D012189:Retrospective Studies
D016179:Granulocyte Colony-Stimulating Factor; D008558:Melphalan